Aarti Pharmalabs Limited

AARTIPHARM

Sector: PharmaceuticalsSub-sector: APIs and Intermediates
Qtr Score Rank 54 / 57 (Top 7 percentile)Growth Score Rank 50 / 51 (Top 4 percentile)

Quarterly Score

Trend: Declining
Concerning decline - Recent 3Q avg 6.27 vs 8Q avg 7.59 (-1.32)

Showing the latest 12 quarterly points (newest to oldest).

Score context (latest 12 quarters)

Q1FY24
6.5

No additional context available.

Q2FY24
7.5

No additional context available.

Q3FY24
7.5

No additional context available.

Q4FY24
7.5

No additional context available.

Q1FY25
7.8

No additional context available.

Q2FY25
7.5

No additional context available.

Q3FY25
8.2

No additional context available.

Q4FY25
8.2

No additional context available.

Q1FY26
7.5

No additional context available.

Q2FY26
6.5

No additional context available.

Q3 FY2026Latest
4.8

Revised downward: Full-year FY26 EBITDA now expected to be flat YoY (previously growth was targeted). CDMO revenue guidance for FY26 is maintained, but management noted that exceeding the target now looks difficult due to project delays.

Quarter summary

  • The quarter was marked by operational stabilization issues at the Atali site, leading to a delay in validation batches and revenue recognition.
  • A significant shift in the Xanthine market occurred with China withdrawing its 13% export rebate, potentially improving Aarti’s pricing power by 8-10% in upcoming quarters.

Rationale

  • Revenue and profitability showed material YoY deterioration in Q3 FY26, with Revenue down 9.8% (₹425 Cr vs ₹471 Cr) and PAT falling 40.5% (₹44 Cr vs ₹74 Cr).
  • Management downgraded FY26 EBITDA guidance from earlier growth expectations to 'largely in line with last year' (flat) due to soft API demand and operational delays.

Future Growth Prospects

Growth score: 6.4Visibility: 60%Updated: 17 Feb 2026, 01:13 am

Catalysts (next 12-24 months)

Total triggers: 4Visible per view: 1 / 2 / 3Slides: 4

Swipe or use arrows to browse all triggers.

capacityQ4 FY26Impact: revenueQty: 4000 units

Xanthine capacity expansion to 9,000 MTPA

• Q3/FY26 · ppt · Xanthine expansion project is progressing as planned. Mechanical completion is expected by Mar’26.

capexQ4 FY26Impact: revenueQty: 450 ₹ Cr

Atali Phase 1 stabilization and CDMO ramp-up

• Q3/FY26 · concall · Atali plant... encountered some starting hiccups... we expect the resolution by end of the current quarter.

productFY27Impact: margin

New API launches (Apixaban and anti-cancer products)

• Q3/FY26 · concall · In 2026, we have a few launches like Apixaban and a few other anticancer products... will see 2026-27 to be a better year overall in terms of API.

capacityFY26EImpact: revenue

Steroid block debottlenecking

• Q3/FY26 · ppt · Steroid block in API production facility will undergo debottlenecking, to create additional capacity.

Variant perception

Non-consensus view
Consensus

Market likely overemphasizing near-term Atali operational hiccups while underappreciating the margin tailwind from China's 13% export rebate removal.

Upside

No upside variants.

Downside

No downside variants.

base case70% conf
Growth: 5

Quick takeaway

Marginal growth in FY26 due to Atali delays and API softness (guided largely in line with ₹427 Cr EBITDA)

Risk watch: Extended Atali stabilization beyond Q4 FY26

Show details (2 drivers, 2 risks)

Drivers

  • Marginal growth in FY26 due to Atali delays and API softness (guided largely in line with ₹427 Cr EBITDA)
  • CDMO growth of 30-40% mostly offset by API pricing pressure

Risks

  • Extended Atali stabilization beyond Q4 FY26
  • Continued generic API pricing erosion
upside case50% conf
Growth: 15

Quick takeaway

Successful blockbuster drug approvals for CDMO partners (POs already in single-digit million dollars)

Risk watch: Regulatory delays in European/US drug approvals

Show details (2 drivers, 2 risks)

Drivers

  • Successful blockbuster drug approvals for CDMO partners (POs already in single-digit million dollars)
  • Rapid Xanthine price jump post-China rebate withdrawal (targeting 20-25% market share)

Risks

  • Regulatory delays in European/US drug approvals
  • Faster than expected Chinese competition response
downside case40% conf
Growth: -5

Quick takeaway

Prolonged operational challenges at Atali Phase 1 impacting qualification batches

Risk watch: Sustained raw material volatility

Show details (2 drivers, 2 risks)

Drivers

  • Prolonged operational challenges at Atali Phase 1 impacting qualification batches
  • Higher depreciation and opex from capitalized units (₹15-16 Cr depreciation on ₹300 Cr Atali cap)

Risks

  • Sustained raw material volatility
  • Further pushback in CDMO project deliveries

Story of the Stock - Top Strategies

Latest Fiscal Years: FY26Top strategies (ranks 1-3) per year
Curated from latest transcripts
Fiscal YearFY26
#1Impact: HIGH

Capacity Expansion in Xanthine Derivatives

Expand capacity to 9,000 MTPA, targeting 20-25% global market share.

Phased commissioning in second half of FY26, fully operational by Q1 FY27.
Show more

Aarti Pharmalabs is expanding its Xanthine derivatives capacity from 5,000 MTPA to 9,000 MTPA, with phased commissioning expected in the second half of FY26. This expansion aims to increase market share and improve profitability.

Impact: 9000 MTPA

Evidence

Capacity expansion ongoing to take total capacity to 9000+ MTPA.
Expected to go live in phased manner in second half of FY26.
Post increased capacity, target to take our global market share of currently 15-20% to 20-25%.
The Xanthine capacity of 9000 MT is likely to be operationalized fully by Q1 FY'27.
#2Impact: HIGH

Greenfield Atali Project for Intermediates and CDMO

Adding 450+ KL reactor volume, expected to boost Intermediates and CDMO/CMO business.

Mechanical completion by Q2-FY26; Ramp up by Q4-FY26.
Show more

The company is commissioning its Atali greenfield site with 450+ KL reactor capacity, focusing on Intermediates and CDMO/CMO segments. This project is expected to be a growth engine for these businesses.

Impact: 450 KL

Evidence

The greenfield project at Atali, Gujarat is in final stages of completion.
Mechanical completion is expected to finish around the end of this current quarter.
It's planned to get operationalized in phases and the full ramp-up is expected by the end of this financial year.
Adding 450+ kL reactor volume in Phase 1, with plans for further expansions. Commercialization expected by FY26 end.
#3Impact: HIGH

Focus on High-Margin CDMO Business Growth

Targeting 30-40% growth in CDMO revenue in FY26, driven by new projects and expanded global sales presence.

Ongoing growth expected, with significant contribution from new projects in FY27-28.
Show more

Aarti Pharmalabs is focusing on growing its CDMO/CMO business, with an estimated sales increase of 30-40% YoY in FY26. This growth is supported by a strong pipeline of projects and an expanding global sales presence in the USA and Europe.

Impact: 40 %

Evidence

CDMO & CMO business growing strong with estimated sales increase of 30-40% YoY in FY26.
Expand on-ground global sales presence in the USA and Europe for CDMO business.
We are presently working with 21 customers on 60 active projects, of which 33 are in the commercial stage and 27 are under different stages of development, both at customer's end.
We have given guidance of 30-40% and we expect this to be achieved by our current product mix of almost 60 products that we have with 21 customers.

Business Segments

Community

Share your view anonymously. Comments are public and sorted newest first.

Anonymous post · 1500 characters left

Loading comments...